Last reviewed · How we verify

CRTE7A2-01 TCR-T cell therapy

Corregene Biotechnology Co., Ltd · Phase 1 active Small molecule

CRTE7A2-01 TCR-T cell therapy is a Small molecule drug developed by Corregene Biotechnology Co., Ltd. It is currently in Phase 1 development. Also known as: CRTE7A2.

At a glance

Generic nameCRTE7A2-01 TCR-T cell therapy
Also known asCRTE7A2
SponsorCorregene Biotechnology Co., Ltd
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CRTE7A2-01 TCR-T cell therapy

What is CRTE7A2-01 TCR-T cell therapy?

CRTE7A2-01 TCR-T cell therapy is a Small molecule drug developed by Corregene Biotechnology Co., Ltd.

Who makes CRTE7A2-01 TCR-T cell therapy?

CRTE7A2-01 TCR-T cell therapy is developed by Corregene Biotechnology Co., Ltd (see full Corregene Biotechnology Co., Ltd pipeline at /company/corregene-biotechnology-co-ltd).

Is CRTE7A2-01 TCR-T cell therapy also known as anything else?

CRTE7A2-01 TCR-T cell therapy is also known as CRTE7A2.

What development phase is CRTE7A2-01 TCR-T cell therapy in?

CRTE7A2-01 TCR-T cell therapy is in Phase 1.

Related